Shares of ASP Isotopes Inc. (NASDAQ:ASPI - Get Free Report) traded up 6.1% on Thursday . The company traded as high as $8.64 and last traded at $8.88. 134,303 shares changed hands during trading, a decline of 96% from the average session volume of 3,198,215 shares. The stock had previously closed at $8.37.
Analysts Set New Price Targets
Separately, Canaccord Genuity Group increased their price target on shares of ASP Isotopes from $8.50 to $11.00 and gave the stock a "buy" rating in a report on Wednesday, May 21st. Two analysts have rated the stock with a Buy rating, Based on data from MarketBeat, ASP Isotopes presently has a consensus rating of "Buy" and a consensus price target of $7.75.
Get Our Latest Analysis on ASP Isotopes
ASP Isotopes Price Performance
The company has a market cap of $824.43 million, a price-to-earnings ratio of -14.70 and a beta of 3.36. The company has a quick ratio of 14.56, a current ratio of 14.72 and a debt-to-equity ratio of 3.53. The stock's 50-day simple moving average is $9.20 and its 200 day simple moving average is $7.21.
ASP Isotopes (NASDAQ:ASPI - Get Free Report) last announced its quarterly earnings results on Thursday, August 14th. The company reported ($1.03) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.92). ASP Isotopes had a negative net margin of 2,181.62% and a negative return on equity of 239.22%. The company had revenue of $1.20 million during the quarter, compared to analysts' expectations of $1.60 million. On average, equities research analysts anticipate that ASP Isotopes Inc. will post -0.24 EPS for the current fiscal year.
Insider Buying and Selling at ASP Isotopes
In other ASP Isotopes news, COO Robert Ainscow sold 8,438 shares of the company's stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $8.53, for a total value of $71,976.14. Following the transaction, the chief operating officer directly owned 1,411,554 shares of the company's stock, valued at $12,040,555.62. This represents a 0.59% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Duncan Moore sold 75,000 shares of the company's stock in a transaction that occurred on Friday, August 29th. The shares were sold at an average price of $9.28, for a total value of $696,000.00. Following the sale, the director directly owned 994,553 shares in the company, valued at approximately $9,229,451.84. This represents a 7.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 245,591 shares of company stock worth $2,139,790. Corporate insiders own 21.40% of the company's stock.
Hedge Funds Weigh In On ASP Isotopes
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Rovida Advisors Inc. purchased a new stake in shares of ASP Isotopes during the 2nd quarter worth about $16,148,000. Rovida Investment Management Ltd boosted its stake in ASP Isotopes by 528.6% in the second quarter. Rovida Investment Management Ltd now owns 2,200,000 shares of the company's stock worth $16,148,000 after purchasing an additional 1,850,000 shares in the last quarter. Exchange Traded Concepts LLC bought a new stake in shares of ASP Isotopes during the second quarter worth $9,593,000. AWM Investment Company Inc. raised its position in shares of ASP Isotopes by 16.0% during the fourth quarter. AWM Investment Company Inc. now owns 4,246,186 shares of the company's stock worth $19,235,000 after acquiring an additional 586,600 shares during the last quarter. Finally, Invesco Ltd. increased its holdings in ASP Isotopes by 2,205.0% in the second quarter. Invesco Ltd. now owns 471,219 shares of the company's stock valued at $3,468,000 after purchasing an additional 450,776 shares during the last quarter. Institutional investors and hedge funds own 16.80% of the company's stock.
About ASP Isotopes
(
Get Free Report)
ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.
Further Reading
Before you consider ASP Isotopes, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ASP Isotopes wasn't on the list.
While ASP Isotopes currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
